APC-Labeled Human CD19 (20-291) Protein, His Tag (Site-specific conjugation)

分子別名（Synonym）

CD19,B4,CVID3,MGC12802

表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）

APC-Labeled Human CD19 (20-291), His Tag (CD9-HA2H5) is produced via conjugation of APC to Human CD19 (20-291), His Tag with a new generation site-specific technology under optimal conditions with a proprietary technology. Human CD19 (20-291), His Tag is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

Predicted N-terminus: Pro 20

蛋白結(jié)構(gòu)（Molecular Characterization）

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 33.7 kDa.

偶聯(lián)（Conjugate）

APC

Excitation Wavelength: 640 nm

Emission Wavelength: 661 nm

應(yīng)用說明（Application）

Please note that this product is NOT compatible to streptavidin detection system.

制劑（Formulation）

Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重構(gòu)方法（Reconstitution）

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存儲(chǔ)（Storage）

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

-20°C to -70°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

背景介紹

B淋巴細(xì)胞抗原CD19（亦稱分化簇19/CD19）是一種單次跨膜I型膜蛋白，包含兩個(gè)免疫球蛋白樣C2型結(jié)構(gòu)域。該蛋白表達(dá)于濾泡樹突狀細(xì)胞及B細(xì)胞表面，具體而言：從發(fā)育早期可識(shí)別的B系祖細(xì)胞直至B母細(xì)胞階段持續(xù)存在，但在成熟為漿細(xì)胞時(shí)消失。CD19主要作為B細(xì)胞共受體，與CD21、CD81協(xié)同作用。其胞質(zhì)尾區(qū)在激活后被磷酸化，進(jìn)而招募Src家族激酶及PI-3激酶形成復(fù)合物。與T細(xì)胞類似，B淋巴細(xì)胞表面多個(gè)分子共同構(gòu)成抗原受體復(fù)合物，其中（幾乎）B細(xì)胞特異性的CD19磷酸糖蛋白是該復(fù)合物的核心組分，其他成員包括CD21與CD81。這些表面免疫球蛋白（sIg）關(guān)聯(lián)分子協(xié)同促進(jìn)信號(hào)轉(zhuǎn)導(dǎo)：活體B細(xì)胞中，模擬外源抗原的抗免疫球蛋白抗體會(huì)引發(fā)CD19與sIg結(jié)合并隨之內(nèi)化。反向過程尚未證實(shí)，提示該受體復(fù)合物的形成具有抗原誘導(dǎo)特性（該分子相互作用已獲生化研究確證）。CD19基因突變可導(dǎo)致抗體產(chǎn)生缺陷型重癥免疫缺陷綜合征。經(jīng)證實(shí)，CD19可與下列分子相互作用：CD81、CD82、補(bǔ)體受體2及VAV2。